Scientists from the University of Queensland have created a new antibiotic that can neutralize various gram-positive bacteria in mice, including major threats such as methicillin-resistant Staphylococcus aureus (MRSA). In a recent study, published in the Sept. 14, 2022, issue of Science Translational Medicine, the new compound outperformed the approved antibiotic vancomycin, and destroyed tough-to-eradicate bacterial biofilms while prompting a low rate of resistance.
Bayer AG has discovered P2X purinoceptor 3 (P2RX3) antagonists reported to be useful for the treatment of overactive bladder, chronic cough, endometriosis, cancer, heart failure, irritable bowel syndrome with diarrhea, pain and sleep apnea, among others.
University of Chicago has described estrogen receptor (ER)-α antagonists reported to be useful for the treatment of cancer, fibroids, uterine (myoma), hormone replacement therapy, menopause, obesity, osteoporosis and atrophic vulvovaginitis.
The Royal Veterinary College has presented drug conjugates comprising hyaluronan (HA) synthesis inhibitors covalently bonded to betaine reported to be useful for the treatment of chondrosarcoma and osteoarthritis.
Gentibio Inc. has announced preclinical data relating to the company's platform technology, demonstrating technical progress to engineer regulatory T cells (Tregs) for the prevention and treatment of autoimmune diseases.
Epivario Inc. has been awarded a grant of nearly $260,000 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) to advance research on its proprietary small-molecule inhibitors designed to reduce alcohol craving responses and help people with alcohol use disorder (AUD) prevent relapse.
Vasoactive intestinal polypeptide receptor 1 (VIPR1) has been shown to have contradicting effects in different cancers. Researchers have investigated the association of VIPR1 with immune inhibitory components to understand its immune landscape.
Researchers from Immatics Biotechnologies GmbH have developed bispecific T-cell engaging receptor (TCER) molecules consisting of an affinity maturated TCR, a humanized T cell-recruiting antibody and an Fc-part conferring half-life extension and favorable stability characteristics.
RSS
